Crossbow Therapeutics

Executive Summary

Crossbow Therapeutics is a preclinical-stage oncology company developing innovative multi-specific antibody therapeutics designed to precisely engage the immune system against solid tumors. Founded in 2021 and headquartered in Cambridge, MA, the company has raised $77 million to advance its proprietary platform that engineers antibodies with unique geometries and signaling capabilities to overcome tumor resistance. Its lead programs target high-unmet-need solid tumors, leveraging a novel approach to harness the immune system more effectively than traditional antibodies. Crossbow's platform is based on rational design and has the potential to address key challenges in cancer immunotherapy, including tumor heterogeneity and immune evasion. The company is currently focused on advancing its lead candidates toward the clinic, with a strong emphasis on preclinical validation and manufacturing scale-up. Backed by a well-funded syndicate, Crossbow is positioned to become a leader in the next generation of antibody-based cancer therapies.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program70% success
• Q4 2026Presentation of Preclinical Data at Major Conference85% success
• Q1 2027Series B Financing or Partnership Announcement60% success